Fulgent to Announce Third Quarter 2024 Financial Results on Friday, November 8, 2024

FLGT 10.17.2024

Full Press ReleaseSEC FilingsOur FLGT Tweets

About Gravity Analytica

Recent News

  • 12.04.2024 - Piper Sandler 36th Annual Healthcare Conference
  • 11.12.2024 - UBS Global Healthcare Conference
  • 11.08.2024 - Q3 2024 Fulgent Genetics Earnings Conference Call

Recent Filings

  • 01.08.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
  • 12.04.2024 - 4 Statement of changes in beneficial ownership of securities
  • 12.02.2024 - 144 Report of proposed sale of securities

EL MONTE, Calif.--(BUSINESS WIRE)--Oct. 17, 2024--Fulgent Genetics, Inc.(NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its third quarter 2024 financial results before the market opens onFriday, November 8, 2024. Management will host a conference call for the investment community the same day at8:30 AM ET(5:30 AM PT) to discuss the results and answer questions.

The call may be accessed through a live audio webcast on the Investor Relations section of the Company’s website,http://ir.fulgentgenetics.com. An audio replay will be available at the same location.

About Fulgent

Fulgent is a technology-based company with a well-established laboratory services business and a therapeutic development business. Fulgent’s laboratory services business, which was formerly referred to as the clinical diagnostic business, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Fulgent’s therapeutic development business is focused on developing drug candidates for treating a broad range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The Company aims to transform from a genomic diagnostic business into a fully integrated precision medicine company.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241017119356/en/

Investor Relations Contact:The Blueshirt GroupMelanie Solomon,melanie@blueshirtgroup.com

Source:Fulgent Genetics, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com